| Withdrawn | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the NCT05717140 | Mayo Clinic | Phase 1 |
| Recruiting | Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants NCT06660420 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02965716 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High NCT03220009 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafe NCT02224781 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations NCT02296112 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Withdrawn | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations NCT02263898 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By NCT02203604 | CINJRegulatory | Phase 2 |
| Completed | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma NCT02107755 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery NCT02120222 | Kari Kendra | Phase 1 |
| Completed | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic NCT02094872 | Yale University | Phase 2 |
| Terminated | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Mel NCT01970527 | University of Washington | Phase 2 |
| Completed | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot B NCT02013492 | William Carson | EARLY_Phase 1 |
| Completed | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma NCT01961115 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Remove NCT01886235 | Roswell Park Cancer Institute | N/A |
| Completed | Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma NCT01898403 | Stanford University | N/A |
| Terminated | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or NCT01835184 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma NCT01744171 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Ipilimumab and Local Radiation for Selected Solid Tumors NCT01769222 | Stanford University | Phase 1 |
| Active Not Recruiting | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Mel NCT01708941 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Region NCT01701037 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors NCT01709435 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma NCT01703507 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery NCT01748747 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | FDG-PET in Advanced Melanoma NCT02236546 | Vanderbilt-Ingram Cancer Center | N/A |
| Withdrawn | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma NCT02507076 | Albert Einstein College of Medicine | N/A |
| Completed | Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Me NCT01339663 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery NCT01533948 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior NCT01519427 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma NCT01316692 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Active Not Recruiting | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has NCT01274338 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma NCT01303341 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Me NCT01307618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Rem NCT01258855 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery NCT01328535 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot B NCT01134614 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV NCT01166126 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma NCT01120275 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and T NCT01196416 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma NCT01103635 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer NCT01037790 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Terminated | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-I NCT00945269 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Dinaciclib in Treating Patients With Stage IV Melanoma NCT00937937 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery NCT00861913 | National Cancer Institute (NCI) | Phase 2 |
| Completed | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma NCT00866177 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma NCT00871481 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Viral Therapy in Treating Patients With Metastatic Melanoma NCT00651157 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma NCT00397982 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma NCT00553306 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Ca NCT00281957 | National Cancer Institute (NCI) | Phase 2 |
| Completed | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00450255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00470470 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melan NCT00438984 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 1 |
| Completed | Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma NCT00436605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma NCT00387751 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery NCT00669019 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma NCT00349206 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma NCT01851408 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma NCT00243061 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By NCT00255762 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion i NCT00303836 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma NCT00288041 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma NCT00121225 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Sta NCT00217542 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV NCT00110019 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors NCT00112476 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655 | Mayo Clinic | Phase 1 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00087373 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Tanespimycin in Treating Patients With Stage III-IV Melanoma NCT00087386 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma NCT00085189 | University of Southern California | Phase 2 |
| Completed | Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma NCT00085306 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | A Phase II Study of UCN-01 in Metastatic Melanoma NCT00072189 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers NCT00074308 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma NCT00072163 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma NCT00060333 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Metastatic Malignant Melanoma NCT00060125 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has NCT01989559 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma NCT01359956 | National Cancer Institute, Naples | Phase 3 |
| Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091 | National Cancer Institute (NCI) | Phase 1 |
| Completed | BMS-247550 in Treating Patients With Stage IV Melanoma NCT00036764 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine in Treating Patients With Advanced Solid Tumors NCT00030615 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma NCT00026221 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma NCT00026143 | National Cancer Institute (NCI) | Phase 2 |
| Completed | PS-341 in Treating Patients With Metastatic Malignant Melanoma NCT00024011 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma NCT00005949 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma NCT00006243 | National Cancer Institute (NCI) | N/A |
| Terminated | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated NCT00006003 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patient NCT01989572 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma NCT00019682 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma NCT00003895 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm NCT00003789 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma NCT00003552 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00019448 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00003646 | Vical | Phase 2 |
| Completed | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma NCT00003647 | Vical | Phase 3 |
| Completed | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer NCT00019396 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma NCT00019890 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positiv NCT02145910 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |